Drug interactions
Dihydroergotamine intranasal + Lapatinib
Severity: Major
Dihydroergotamine intranasal and Lapatinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
CYP3A4 inhibition by lapatinib can raise systemic dihydroergotamine levels and risk ergotism. This presents as severe peripheral vasospasm and ischemia of the limbs or brain.
What this interaction means in plain words
Dihydroergotamine intranasal and Lapatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Lapatinib inhibits CYP3A4 metabolism of dihydroergotamine.
What to do
Avoid the combination and use a non-ergot migraine therapy. If co-administered, watch for numbness, cold extremities and ischemic symptoms.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dihydroergotamine intranasal and Lapatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Frequently asked questions
Can I take Dihydroergotamine intranasal with Lapatinib?
MediHelp rates the interaction as major. Dihydroergotamine intranasal and Lapatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. CYP3A4 inhibition by lapatinib can raise systemic dihydroergotamine levels and risk ergotism. This presents as severe peripheral vasospasm and ischemia of the limbs or brain.
How serious is the interaction between Dihydroergotamine intranasal and Lapatinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and use a non-ergot migraine therapy. If co-administered, watch for numbness, cold extremities and ischemic symptoms.
What other medicines interact with Lapatinib?
MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
